Susan Klaeger

Susan Klaeger

Auto-generated profile, based on publicly available information

Susan Klaeger

Broad Institute of MIT and Harvard, Cambridge, MA, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2014 in Science
Verified
Journal Article
Closed access
PDF file
MSMikhail M. Savitski
Mikhail M. Savitski
FRFriedrich B. M. Reinhard
Friedrich B. M. Reinhard
HFHolger Franken
Holger Franken
TWThilo Werner
Thilo Werner
MSMaria Fälth Savitski
Maria Fälth Savitski
GDGerard Drewes
Gerard Drewes
Mapping human drug targets in the cell: To understand both the beneficial and the side effects of a drug, one would need to know its full binding profile to all cellular proteins. Savitskiet al.take significant steps toward meeting this daunting challenge. They monitored the unfolding or “melting” of over 7000 human proteins and measured how small-molecule binding changes individual melting profiles. As a proof of principle, over 50 targets were identified for an inhibitor known to bind a broad spectrum of kinases. Two cancer drugs, vemurafib and Alectinib, are known to have a side effect of photosensitivity. The thermal profiling approach identified drug-protein interactions responsible for these side effects.Science, this issue10.1126/science.1255784

1 December 2017 in Science
Verified
Journal Article
Open access
PDF file
SKSusan Klaeger
Susan Klaeger
SHStephanie Heinzlmeir
Stephanie Heinzlmeir
MWMathias Wilhelm
Mathias Wilhelm
HPHarald Polzer
Harald Polzer
BVBinje Vick
Binje Vick
BKBernhard Kuster
Bernhard Kuster
An atlas for drug interactions: Kinase inhibitors are an important class of drugs that block certain enzymes involved in diseases such as cancer and inflammatory disorders. There are hundreds of kinases within the human body, so knowing the kinase “target” of each drug is essential for developing successful treatment strategies. Sometimes clinical trials can fail because drugs bind more than one target. Yet sometimes off-target effects can be beneficial, and drugs can be repurposed for treatment of additional diseases. Klaegeret al.performed a comprehensive analysis of 243 kinase inhibitors that are either approved for use or in clinical trials. They provide an open-access resource of target summaries that could help researchers develop better drugs, understand how existing drugs work, and design more effective clinical trials.Science, this issue p.eaan4368

21 July 2021 in Nature
Verified
Journal Article
Closed access
PDF file
GOGiacomo Oliveira
Giacomo Oliveira
KSKari Stromhaug
Kari Stromhaug
SKSusan Klaeger
Susan Klaeger
TKTomasz Kula
Tomasz Kula
DFDennie T. Frederick
Dennie T. Frederick
CWCatherine J. Wu
Catherine J. Wu

16 December 2019 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
SSSiranush Sarkizova
Siranush Sarkizova
SKSusan Klaeger
Susan Klaeger
PLPhuong M. Le
Phuong M. Le
LLLetitia W. Li
Letitia W. Li
GOGiacomo Oliveira
Giacomo Oliveira
DKDerin B. Keskin
Derin B. Keskin

5 May 2021 in Nature
Verified
Journal Article
Closed access
PDF file
GGGabriel K. Griffin
Gabriel K. Griffin
JWJingyi Wu
Jingyi Wu
AIArvin Iracheta-Vellve
Arvin Iracheta-Vellve
JPJames C. Patti
James C. Patti
JHJeffrey Hsu
Jeffrey Hsu
BBBradley E. Bernstein
Bradley E. Bernstein

18 October 2021 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
TOTamara Ouspenskaia
Tamara Ouspenskaia
TLTravis Law
Travis Law
KCKarl R. Clauser
Karl R. Clauser
SKSusan Klaeger
Susan Klaeger
SSSiranush Sarkizova
Siranush Sarkizova
ARAviv Regev
Aviv Regev